Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasm, Residual 1Medulloblastoma 1Leukemia, Hairy Cell 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 6X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Biopsy 5Cyclophosphamide 3ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Temozolomide 2Etoposide 2tazemetostat 1pembrolizumab 1palbociclib 1omburtamab I-131 1olaparib 1etoposide phosphate 1dostarlimab 1abemaciclib 1Vemurafenib 1Triiodothyronine 1Surgical Procedures, Operative 1Sirolimus 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ependymoma × Histamine Antagonists × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡